Masato Takahashi1, Shoichiro Ohtani2, Shigenori E Nagai3, Seiki Takashima4, Miki Yamaguchi5, Michiko Tsuneizumi6, Yoshifumi Komoike7, Tomofumi Osako8, Yoshinori Ito9, Masahiko Ikeda10, Kazushige Ishida11, Takahiro Nakayama12, Tsutomu Takashima13, Takashi Asakawa14, Sho Matsumoto15, Daisuke Shimizu16, Norikazu Masuda17. 1. Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. 2. Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. 3. Breast Oncology, Saitama Cancer Center, Saitama, Japan. 4. Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. 5. Breast Surgery, JCHO Kurume General Hospital, 21 Kushihara-machi Kurume, Fukuoka, Japan. 6. Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan. 7. Surgery, Kindai University Hospital, Osakasayama, Japan. 8. Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan. 9. Breast Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan. 10. Breast and Thyroid Surgery, Fukuyama City Hospital, Hiroshima, Japan. 11. Surgery, Iwate Medical University, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate Prefecture, 028-3695, Japan. 12. Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan. 13. Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi Abeno-ku, Osaka, 5458585, Japan. 14. Clinical Information and Intelligence Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan. 15. Clinical Study Management Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan. 16. Clinical Science and Strategy Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan. 17. Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan. nmasuda@alpha.ocn.ne.jp.
Abstract
PURPOSE: In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzumab plus trastuzumab and docetaxel vs. placebo that was seen in the overall population. Therefore, COMACHI was conducted to confirm the efficacy and safety of this treatment regimen in this patient subgroup. METHODS: This was a phase IV study of pertuzumab plus trastuzumab and docetaxel in Japanese patients with histologically/cytologically confirmed inoperable or recurrent HER2-positive breast cancer. All patients received pertuzumab, trastuzumab, and docetaxel intravenously every 3 weeks until disease progression/unacceptable toxicity. The primary endpoint was investigator-assessed PFS. Secondary endpoints were overall survival (OS), investigator-assessed objective response rate, and duration of response (DoR). Safety was also assessed. RESULTS: At final analysis, median investigator-assessed PFS was 22.8 months (95% CI 16.9-37.5). From first dose, OS rate at 1 year was 97.7%; and at 2 and 3 years were 88.5% and 79.1%, respectively. Of the 118 patients with measurable disease at baseline, response rate was 83.9% (95% CI 77.3-90.5) and median investigator-assessed DoR was 26.3 months (95% CI 17.1-not evaluable). Treatment was well tolerated, with no new safety signals detected. CONCLUSIONS: Our results suggest similar efficacy and safety for pertuzumab plus trastuzumab and docetaxel in Japanese patients compared with the overall population of CLEOPATRA, providing further support for this combination therapy as standard of care for Japanese patients with inoperable or recurrent HER2-positive breast cancer.
RCT Entities:
PURPOSE: In the CLEOPATRA study of patients with humanepidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzumab plus trastuzumab and docetaxel vs. placebo that was seen in the overall population. Therefore, COMACHI was conducted to confirm the efficacy and safety of this treatment regimen in this patient subgroup. METHODS: This was a phase IV study of pertuzumab plus trastuzumab and docetaxel in Japanese patients with histologically/cytologically confirmed inoperable or recurrent HER2-positive breast cancer. All patients received pertuzumab, trastuzumab, and docetaxel intravenously every 3 weeks until disease progression/unacceptable toxicity. The primary endpoint was investigator-assessed PFS. Secondary endpoints were overall survival (OS), investigator-assessed objective response rate, and duration of response (DoR). Safety was also assessed. RESULTS: At final analysis, median investigator-assessed PFS was 22.8 months (95% CI 16.9-37.5). From first dose, OS rate at 1 year was 97.7%; and at 2 and 3 years were 88.5% and 79.1%, respectively. Of the 118 patients with measurable disease at baseline, response rate was 83.9% (95% CI 77.3-90.5) and median investigator-assessed DoR was 26.3 months (95% CI 17.1-not evaluable). Treatment was well tolerated, with no new safety signals detected. CONCLUSIONS: Our results suggest similar efficacy and safety for pertuzumab plus trastuzumab and docetaxel in Japanese patients compared with the overall population of CLEOPATRA, providing further support for this combination therapy as standard of care for Japanese patients with inoperable or recurrent HER2-positive breast cancer.
Entities:
Keywords:
Docetaxel; HER2-positive inoperable/recurrent/advanced/metastatic breast cancer; Japanese patients; Pertuzumab; Prospective clinical trial; Trastuzumab
Authors: José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Sandra M Swain; Young-Hyuck Im; Seock-Ah Im; Valorie Chan; David Miles; Adam Knott; Emma Clark; Graham Ross; José Baselga Journal: Oncologist Date: 2014-05-28
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Bella Kaufman; John R Mackey; Michael R Clemens; Poonamalle P Bapsy; Ashok Vaid; Andrew Wardley; Sergei Tjulandin; Michaela Jahn; Michaela Lehle; Andrea Feyereislova; Cédric Révil; Alison Jones Journal: J Clin Oncol Date: 2009-09-28 Impact factor: 44.544
Authors: Sandra M Swain; Sung-Bae Kim; Javier Cortés; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Adam Knott; Emma Clark; Graham Ross; Mark C Benyunes; José Baselga Journal: Lancet Oncol Date: 2013-04-18 Impact factor: 41.316
Authors: Jeffrey S Ross; Elzbieta A Slodkowska; W Fraser Symmans; Lajos Pusztai; Peter M Ravdin; Gabriel N Hortobagyi Journal: Oncologist Date: 2009-04-03
Authors: Wei Fang Dai; Jaclyn M Beca; Chenthila Nagamuthu; Ning Liu; Claire de Oliveira; Craig C Earle; Maureen Trudeau; Rebecca E Mercer; Kelvin K W Chan Journal: JAMA Netw Open Date: 2022-02-01